pro-TGF-beta 1

€539.00

Price excl. shipping costs excl. VAT. For more information, see our shipping policy

SKU: P2020-115 trenzyme

Need a quote for an individual request or for a bulk order?

Please contact us.

Description

Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-1 (TGF-beta-1) chains, which constitute the regulatory and active subunit of TGF-beta-1, respectively.

Overview

  • Product Name: pro-TGF-beta 1, His-Tag
  • Catalog No.: P2020-115
  • RefSeq Links: UniProt: P01137; NP_000651.3; NM_000660.6; PDB: 1KLA
  • Synonyms: Latent TGF‑β1,  small latent TGF-β1 complex, Transforming growth factor beta-1 proprotein, Latency-associated peptide, Transforming growth factor beta 1, TGF-β1

Sequence Information

  • Species: Homo sapiens, human
  • Tags: His-Tag, N-terminal
  • Sequence without tags (AA 30-390):
    MELVKRKRIEAIRGQILSKLRLASPPSQGEVPPG
    PLPEAVLALYNSTRDRVAGESAEPEPEPEADYYAKEVTRVLMVETHNEIYDKFKQSTHSI
    YMFFNTSELREAVPEPVLLSRAELRLLRLKLKVEQHVELYQKYSNNSWRYLSNRLLAPSD
    SPEWLSFDVTGVVRQWLSRGGEIEGFRLSAHCSCDSRDNTLQVDINGFTTGRRGDLATIH
    GMNRPFLLLMATPLERAQHLQSSRHRRALDTNYCFSSTEKNCCVRQLYIDFRKDLGWKWI
    HEPKGYHANFCLGPCPYIWSLDTQYSKVLALYNQHNPGASAAPCCVPQALEPLPIVYYVG
    RKPKVEQLSNMIVRSCKCS

Product Information

  • Expression Host: human, HEK293
  • Formulation: PBS; pH 7.4.
  • Format: Liquid, stored and shipped at -80°C
  • Purity: > 95% as determined by SDS-PAGE

Background Information

Transforming growth factor beta 1 (TGF-β1) belongs to the transforming growth factor beta superfamily of cytokines and is involved in a myriad of cellular functions including the control of cell growth, cell proliferation, cell differentiation, and apoptosis.
The transforming growth factor beta-1 is synthesized as precursor consisting of the latency-associated peptide (LAP, 249 aa) and the transforming growth factor beta 1 (112 aa). The precursor is also named small latend complex (SLC) or latent TGF-ß1. The precursor proprotein is cleaved in the Golgi apparatus by Furin, but the disulfide-linked homodimers of LAP and TGF-beta 1 remain non‑covalently associated after secretion.
TGF-ß1 activation from latency is controlled both spatially and temporally, by multiple pathways that include actions of proteases such as plasmin and MMP9, and/or by thrombospondin 1 or selected integrins. Once activated following release of LAP, TGF-beta-1 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signals.

Mutations within the LAP are associated with Camurati-Engelmann disease, a rare sclerosing bone dysplasia characterized by inappropriate presence of active TGF-beta 1.


SDS-PAGE/Coll. Coomassie

Histogram of marked lane in gel picture

SDS-PAGE of pro-TGF-beta 1 Histogram (of marked lane in gel picture) pro-TGF-beta 1

Get in contact with us


By submitting this form, I consent to trenzyme GmbH receiving and processing my data in order to process my inquiry. My consent is voluntary and I may revoke this consent at any time without providing any reasons, e.g. by sending an email to privacy(at)trenzyme.com with effect for the future. Further notices on data processing can be found in our privacy policy.